Close Menu

Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, Cameron Turtle

Feb 12, 2019

Caribou Biosciences has appointed Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, and Cameron Turtle to its scientific advisory board. 

Balskus is a professor of chemistry and chemical biology at Harvard University and an associate member of the Broad Institute of Harvard and MIT. Bhatt is an assistant professor of medicine (hematology) and genetics at Stanford University. Lee is a professor of pediatrics at Nationwide Children's Hospital and Ohio State University, and is also the founding director of the joint cellular therapy and cancer immunotherapy program between the Research Institute at Nationwide Children's Hospital and Ohio State University Comprehensive Cancer Center. Rathmell serves as director of the Vanderbilt Center for Immunobiology and as associate director of the Institute of Infection, Immunology and Inflammation at the Vanderbilt University Medical Center. Raje is a professor of Medicine at Harvard Medical School, director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. And Turtle is an associate member at Fred Hutchinson Cancer Research Center and an associate professor at the University of Washington.

The new members will join current scientific advisory board members and Caribou cofounders Jennifer Doudna and Martin Jinek.

More Like This

Nov 22, 2019

Inteliquet: Marie Lamont

Inteliquet has named Marie Lamont interim president and chief operating officer. She replaces former CEO, President, and COO Carla Balch, who left Inteliquet to "pursue other opportunities," the company said. Lamont had been president of patient services at Dolman Life Science Services. Previously, she held several senior positions at Genzyme. Inteliquet rebranded from TransMed Systems earlier this year.

Nov 21, 2019

NYGC: Mary-Claire King

Mary-Claire King has joined the New York Genome Center faculty on a consulting basis as a senior associate core member. She is the American Cancer Society Professor in the Department of Genome Sciences and Medicine at the University of Washington in Seattle. At the NYGC, she will work closely with Thomas Lehner, the center's recently appointed scientific director of neuropsychiatric disease, and act as a senior adviser to both Lehner and Tom Maniatis, the center's CEO.  

Nov 21, 2019

Elucidata: Richard Kibbey, Nick Pullen, Avi Ma'ayan

Elucidata has formed a scientific advisory board comprising Richard Kibbey, Nick Pullen, and Avi Ma'ayan. Kibbey is associate professor of medicine (endocrinology) and cellular & molecular biology at the Yale School of Medicine. Pullen is the scientific cofounder of Elucidata, and has more than 20 years of experience in the pharmaceutical industry with Pfizer, Roche, and most recently Celgene. Ma'ayan is director of the Mount Sinai Center for Bioinformatics and a professor of bioinformatics in Mount Sinai's Department of Pharmacological Sciences.

Nov 20, 2019

Twist Bioscience: Patrick Finn

Patrick Finn has been promoted from senior VP of commercial operations to chief operating officer of Twist Bioscience, a new position at the company. Prior to joining Twist in 2015, Finn was VP of sales at Enzymatics, and before that, he held various positions at Agilent Technologies, Beckman Coulter, Invitrogen, and GE Healthcare/Amersham International. He holds a PhD in nucleic acid chemistry from the University of Southampton in England and a BSc in chemistry from Heriot-Watt University in Scotland.

Nov 20, 2019

GenapSys: Frank Witney, Rakesh Sachdev, Hamid Moghadam

In connection with its recent funding round, GenapSys has made several appointments to its board of directors. Joining the board are Frank Witney, former CEO of Affymetrix and Dionex; Rakesh Sachdev, former CEO of Sigma Aldrich and Platform Specialty Products; and Hamid Moghadam, CEO and chairman of Prologis.

Nov 20, 2019

BioTeam: Ari Berman, Stan Gloss

Ari Berman has been promoted from VP of consulting to CEO of BioTeam. He replaces company cofounder Stan Gloss, who will become BioTeam's chief marketing officer. Berman holds a PhD in molecular biology from the University of Texas at Austin.

Nov 20, 2019

ATCC: Raymond Stapleton

Raymond Stapleton has been appointed as president and chief operating officer of biological materials resource and standards organization ATCC. Previously, he was senior VP of technical operations at Iovance Biotherapeutics, and before that, he held various roles at Merck. Stapleton holds a PhD in microbial ecology from the University of Tennessee and a bachelor's degree in biology from Mary Washington College in Fredericksburg, Virginia.

Nov 20, 2019

Sophia Genetics: Milton Silva-Craig

Sophia Genetics has named Milton Silva-Craig to its board of directors. Silva-Craig currently serves as CEO of Q-Centrix, a maker of healthcare data management technology. He previously headed the healthcare business unit of TransUnion and was president and CEO of Emageon, a health imaging software company that he helped lead through an initial public offering before that firm was sold to revenue-cycle management technology vendor Health Systems Solutions.

Nov 14, 2019

SEngine Precision Medicine: Astrid Margossian

SEngine Precision Medicine has hired Astrid Margossian as chief medical officer. Margossian, a surgeon, medical oncologist, and cancer researcher with MD and PhD degrees, previously established and served as medical director of Baylor College of Medicine's Breast Center Buenos Aires and Breast Cancer Research Biobank, which focuses on biomarker discovery for breast cancer. 

Nov 14, 2019

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

Nov 13, 2019

Danaher: Jessica Mega, Pardis Sabeti

Danaher has appointed Jessica Mega and Pardis Sabeti to its board of directors. Mega has been the chief medical and scientific officer at Verily Life Sciences since October 2015, and was previously a cardiologist and senior investigator at Brigham & Women's. She has also been a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group. Mega holds degrees from Stanford University, Yale University School of Medicine, and Harvard School of Public Health.

Sabeti has been an investigator at Howard Hughes Medical Institute since November 2015, and is also a professor at the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University. She also teaches in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Sabeti holds degrees from the Massachusetts Institute of Technology, University of Oxford, and Harvard Medical School. 

Nov 13, 2019

Human Longevity: Thomas Caskey

Human Longevity has appointed Thomas Caskey as chief medical officer. Caskey is a professor of molecular and human genetics at the Baylor College of Medicine, and is board-certified in internal medicine, medical genetics, and molecular genetics. He is a member of the National Academy of Sciences, Institute of Medicine, Royal Society of Canada and the Texas Academy of Medicine, Engineering and Science. He is also past president of the American Society of Human Genetics and the Human Genome Organization. 

Nov 13, 2019

Abbott: Robert Ford, Miles White

Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board. 

Nov 12, 2019

Prescient Medicine Holdings: Tony Grover

Tony Grover has been named the chief commercial officer of Prescient Medicine Holdings where he will build and execute go-to-market strategies. Grover was vice president of business development at Banyan Biomarkers. Prior to that, he held various positions at PhotoThera. His immediate focus at Prescient will be the LifeKit Predict test, an in vitro diagnostic test for identifying patients at risk of opioid addiction. The test received breakthrough device designation in February 2018. Another test, LifeKit Prevent, for the detection of precancerous polyps and early-stage carcinomas, received breakthrough device designation in August 2019. 

Nov 07, 2019

Armonica Technologies: Victor Esch

Armonica Technologies, an Albuquerque, New Mexico-based firm developing long-read DNA sequencing technology, has appointed Victor Esch as president and CEO. Esch has more than twenty years of executive and technical experience in the medical device industry, including as CEO of DNA Electronics and CEO of nanoMR, which DNA Electronics acquired in 2015. Esch was a founder of Powervision, which was acquired by Alcon in 2019. He also previously served as chief technology officer for EndoVasix.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.